Generate Biomedicines' (GENB) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated its Buy rating on Generate Biomedicines and set a $30 price target, implying approximately 88% upside from the stock’s $15.96 price.
• Analyst sentiment is generally positive: six analysts rate the stock Buy, one rates it Hold, and one rates it Sell, resulting in a consensus “Moderate Buy” rating and an average target price of $26.40.
• Generate Biomedicines reported quarterly revenue of $6.31 million and an adjusted loss of $0.52 per share, missing the consensus loss estimate of $0.48; analysts expect a full-year loss of $2.29 per share.

Generate Biomedicines (NASDAQ:GENB - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $30.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 87.97% from the stock's current price.

A number of other equities analysts have also commented on the stock. Morgan Stanley lifted their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Generate Biomedicines from a "sell" rating to a "hold" rating in a report on Saturday, August 29th. Finally, Weiss Ratings started coverage on Generate Biomedicines in a report on Tuesday, August 11th. They issued a "sell (d)" rating on the stock. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $26.40.

Generate Biomedicines Price Performance

NASDAQ:GENB traded down $0.43 during trading hours on Tuesday, hitting $15.96. The company's stock had a trading volume of 684,195 shares, compared to its average volume of 782,372. The stock has a fifty day simple moving average of $15.26. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $22.67. The stock has a market capitalization of $2.05 billion and a P/E ratio of -9.99.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The company had revenue of $6.31 million for the quarter. Equities research analysts forecast that Generate Biomedicines will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Braidwell LP purchased a new position in Generate Biomedicines in the second quarter worth $55,398,000. Bank of New York Mellon Corp purchased a new position in Generate Biomedicines during the 2nd quarter valued at about $967,000. AXQ Capital LP purchased a new stake in Generate Biomedicines in the second quarter worth $218,000. Susquehanna International Group LLP bought a new stake in Generate Biomedicines during the 2nd quarter valued at approximately $196,000. Finally, California State Teachers Retirement System purchased a new stake in Generate Biomedicines in the second quarter worth $96,000.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.